GlassScriptPhysician profile
Subhash Kshetrapal
NPI 1427086131
$9,376.83
in general payments reported to CMS, 2019-2025
17 companies · $426 in 2025
The $426 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $730 · 2020: $239 · 2021: $613 · 2022: $716 · 2023: $3,520 · 2024: $3,133 · 2025: $426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,806 · Travel and Lodging: $3,272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,806.30 |
| Travel and Lodging | $3,272.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $5,154.85 | 2019-2024 | Optis, Aveir, Diamondback Coronary |
| Boston Scientific Corporation | $2,267.97 | 2019-2025 | General - Stents, Synergy, General - Vascular Access |
| Medtronic, INC. | $1,078.82 | 2021-2025 | Aurora Ev-Icd Mri Surescan, Micra, Azure Xt Dr Mri Surescan |
| Abiomed | $239.81 | 2019-2024 | Impella |
| Impulse Dynamics (USA) INC. | $153.17 | 2024 | Optimizer |
| Edwards Lifesciences Corporation | $122.97 | 2022 | |
| Chiesi USA, INC. | $65.81 | 2023 | Kengreal |
| Preventice Services, LLC | $45.43 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $41.93 | 2024-2025 | Lifevest |
| Astrazeneca Uk Limited | $38.07 | 2019 | |
| Amgen INC. | $32.70 | 2019 | |
| Janssen Pharmaceuticals, INC | $29.63 | 2019 | |
| Medtronic Vascular, INC. | $28.97 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $25.37 | 2019 | |
| Cardiovascular Systems INC. | $19.73 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $15.96 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Subhash Kshetrapal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.